AQR Capital Management LLC Purchases Shares of 27,287 Allogene Therapeutics, Inc. (NASDAQ:ALLO)

AQR Capital Management LLC acquired a new stake in Allogene Therapeutics, Inc. (NASDAQ:ALLO) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 27,287 shares of the company’s stock, valued at approximately $64,000.

Other large investors have also added to or reduced their stakes in the company. Nisa Investment Advisors LLC grew its stake in Allogene Therapeutics by 429.6% during the second quarter. Nisa Investment Advisors LLC now owns 10,767 shares of the company’s stock worth $25,000 after purchasing an additional 8,734 shares during the period. Federated Hermes Inc. acquired a new stake in Allogene Therapeutics during the second quarter worth approximately $29,000. Phoenix Wealth Advisors bought a new position in Allogene Therapeutics in the second quarter worth approximately $30,000. Headlands Technologies LLC bought a new position in Allogene Therapeutics in the first quarter worth approximately $78,000. Finally, CANADA LIFE ASSURANCE Co boosted its holdings in Allogene Therapeutics by 85.1% in the first quarter. CANADA LIFE ASSURANCE Co now owns 17,750 shares of the company’s stock worth $79,000 after acquiring an additional 8,162 shares in the last quarter. Institutional investors and hedge funds own 83.63% of the company’s stock.

Allogene Therapeutics Stock Performance

NASDAQ:ALLO opened at $2.84 on Friday. The firm has a market capitalization of $593.56 million, a price-to-earnings ratio of -1.59 and a beta of 0.83. Allogene Therapeutics, Inc. has a 52-week low of $2.01 and a 52-week high of $5.78. The stock has a fifty day moving average of $2.65 and a 200 day moving average of $2.77.

Allogene Therapeutics (NASDAQ:ALLO) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.03. Allogene Therapeutics had a negative return on equity of 50.24% and a negative net margin of 223,139.98%. Equities analysts forecast that Allogene Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $9.00 price target on shares of Allogene Therapeutics in a report on Thursday, August 15th. Truist Financial restated a “buy” rating and issued a $14.00 target price (down previously from $17.00) on shares of Allogene Therapeutics in a report on Friday, August 9th. Oppenheimer initiated coverage on Allogene Therapeutics in a report on Thursday, August 8th. They issued an “outperform” rating and a $11.00 target price on the stock. Canaccord Genuity Group dropped their target price on Allogene Therapeutics from $35.00 to $14.00 and set a “buy” rating on the stock in a report on Thursday, August 8th. Finally, Citigroup raised their target price on Allogene Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a report on Friday, August 9th. Three analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, Allogene Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $9.96.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).